Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open Label Study to Evaluate the Safety Profile and the Quality of Life in Patients Receiving Etanercept for the Treatment of Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis.

Next Previous
X
Search
Trial Profile

Open Label Study to Evaluate the Safety Profile and the Quality of Life in Patients Receiving Etanercept for the Treatment of Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis.

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 14 Sep 2011

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Etanercept (Primary)
  • Indications Ankylosing spondylitis; Psoriatic arthritis; Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors Wyeth

    • Most Recent Events

    • 23 Sep 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 23 Sep 2010 Planned end date changed from 1 Sep 2011 to 1 Jul 2010 as reported by ClinicalTrials.gov.
    • 24 Mar 2010 Planned number of patients changed from 1000 to 909 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top